PGGT1B

Across TCGA pan-cancer cohorts, PGGT1B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PGGT1B data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PGGT1B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated PGGT1B expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, HNSC, and LUSC are the cancer types where PGGT1B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	1.000	0.627	.012	24	view →
HNSC	DFS	Median	II,III,IV	0.094	0.697	<.001	18	view →
LUSC	OS	Median	All	0.173	0.724	.012	15	view →
ESCA	OS	Median	II,III,IV	0.206	0.686	.004	12	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PGGT1B–UCEC (DFS)

Open the UCEC breakdown →